The company has claimed that compounded semaglutide with incorrect dosages and 'known and unknown' impurities have been given to patients in the US, saying earlier this year that it was aware of more than 400 adverse events associated with the drugs
#HealthInnovation #WeightLoss #ChronicCare #PublicHealth #GLP-1 To view or add a comment, sign in New research published in the The BMJ adds an important perspective to the growing discussion around GLP-1 weight-loss medications and what happens when treatment is stopped
It requires proactive blood sugar monitoring and communication with your prescriber about dose adjustments as weight changes
Orlistat Alternatives for Weight Loss in Germany: What Are Your Options
Coupled with the overall rise in GLP-1 RA-related discussions after the 2021 FDA approval of semaglutide for weight loss, we identify a high public interest in the use of these medications for weight management, despite their original intended use in diabetes
The authors framed the data as first clear evidence that NNMT inhibitors constitute a viable pharmacological approach to enhance regenerative capacity in aged skeletal muscle
